DoseMe, the first company in the world to design a precision dosing platform - DoseMeRx - specifically developed for clinical practice today announced it will be acquired by Tabula Rasa HealthCare, Inc (NASDAQ:TRHC) a healthcare technology company advancing the field of medication safety. Tabula Rasa HealthCare (“TRHC”)...
Read more
Earlier this month, Dr William Musick, Director of the PGY2 Infectious Diseases Pharmacy Residency program at Houston Methodist and Dr. Ryan Keul, Clinical Pharmacy Specialist for Antibiotic Stewardship at Texas Children's Hospital shared their experience with DoseMeRx for vancomycin monitoring and a case study on busulfan dosing during a...
Read more
THE CURRENT LANDSCAPE Intravenous (IV) Busulfan is an alkylating drug routinely used in conditioning regimens before allogenic haemopoietic cell transplantation (HCT), the standard treatment for various malignant and non-malignant disorders. However, drug exposure must be maintained within a narrow therapeutic range. If the drug exposure is too high, there is...
Read more
DoseMe as the world’s first company to design a precision dosing platform for clinical use - DoseMeRx - will attend and exhibit at the American Society of Health System Pharmacists Midyear Clinical Meeting from December 2-6 in Anaheim, California. DoseMeRx allows healthcare professionals to dose a patient based on their...
Read moreHIPAA Privacy Statement | Privacy policy | DoseMe & the GDPR | Copyright © 2012 - 2018 DoseMe Pty Ltd. All Rights Reserved.
DoseMe® is a registered trademark of DoseMe Pty Ltd. DoseMeRx℠ and DoseMe℞℠ are service marks of DoseMe LLC.
